Kuhnil & Daiichi Sankyo’s joint sales of dyslipidemia treatment ‘Mevalotin’
For ‘Mevalotin(generic name: pravastatin),’ the dyslipidemia treatment, Kuhnil Pharm(CEO Young-Joong Kim) and Daiichi Sankyo Korea(CEO Dae-Joong Kim) will started the joint sales from the 1st of April.
Daiichi Sankyo Korea will end the joint marketing with LG Chem on the 31st of March and chose ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
